

Publications from the Connect® Myeloid Disease Registry

Updated July 1, 2021

This list includes published manuscripts and abstracts made available from study start to June 2021.

MANUSCRIPTS

2020

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Flick ED, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. *International Journal of Laboratory Hematology*. 2020, November 21. Epub ahead of print. <https://doi.org/10.1111/ijlh.13400>.

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukaemia in the Connect® MDS/AML disease registry. Pollyea DA, George TI, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Thompson MA, Kurtin SE, Louis CU, Nifenecker M, Flick ED, Swern AS, Kiselev P, Steensma DP, Erba HP. *eJHaem*. 2020; 1:58-68.

2016

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. *BMC Cancer*. 2016;16:652-662.

ABSTRACTS

2021

Health-related quality of life in patients with myelodysplastic syndromes in the Connect® Myeloid Disease Registry. Revicki DA, Grinblatt DL, Komrokji RS, Garcia-Manero G, Savona MR, Scott BL, Sekeres MA, Flick ED, Makinde AY, Kiselev P, Louis CU, Nifenecker M, DeGutis IS, Cogle CR. *HemaSphere* 2021;5:(S2):568.

Health-related quality of life in patients with myelodysplastic syndromes in the Connect® Myeloid Disease Registry. Revicki DA, Grinblatt DL, Komrokji RS, Garcia-Manero G, Savona MR, Scott BL, Sekeres MA, Flick ED, Makinde AY, Kiselev P, Louis CU, Nifenecker M, DeGutis IS, Cogle CR. *J Clin Oncol*. 2021;39(suppl 15):7040.

Post-remission treatment patterns for patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry. Roboz GJ, Cogle CR, Pollyea DA, Abedi M, Thompson MA, Nifenecker M, Flick ED, Kiselev P, Louis CU, Little M, DeGutis I, Erba HP. EBMT 2021 Abstract P005.

2020

Post-remission treatment patterns for patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML disease registry. Roboz GJ, Cogle CR, Pollyea DA, Abedi M, Thompson MA, Nifenecker M, Flick ED, Kiselev P, Louis CU, Little M, DeGutis I, Erba HP. *Blood*. 2020;136(suppl 1):26-27.

Changing molecular diagnostic testing patterns for patients with myelodysplastic syndromes and acute myeloid leukemia in the Connect® MDS/AML disease registry. George TI, Abedi M, Cogle CR, Erba HP, Garcia-Manero G, Grinblatt DL, Kiselev P, Komrokji RS, Louis CU, Maciejewski J, Nifenecker M, Pollyea DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Patel JL. ASH 2020 Abstract 1617.

Molecular and diagnostic testing patterns in elderly patients with myelodysplastic syndromes (MDS) in the Connect® MDS/AML disease registry. George TI, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Savona MR, Scott BL, Sekeres MA, Steensma DP, Flick DE, Kiselev P, Louis CU, Nifenecker M, Swern AS, Foucar K. *Clin Lymph Myeloma Leuk*. 2020;20(suppl 1):S128-129.

Molecular/diagnostic testing patterns in elderly patient (pts) with acute myeloid leukemia (AML) in the Connect® MDS/AML disease registry. George TI, Abedi M, Erba HP, Kurtin SE, Maciejewski J, Pollyea DA, Roboz GJ, Thompson MA, Flick ED, Kiselev P, Louis CU, Nifenecker M, Swern AS, Foucar K. *HemaSphere*. 2020;4(suppl 1):EP622.

Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect® MDS/AML disease registry. George TI, Patel JL, Abedi M, Cogle CR, Erba HP, Garcia-Manero G, Grinblatt DL, Kiselev P, Komrokji RS, Louis CU, Maciejewski J, Nifenecker M, Pollyea DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Foucar K. *J Clin Oncol*. 2020;38(suppl15):7553.

Transplant referral patterns for patients (pts) with newly diagnosed (ND) higher-risk (HR) myelodysplastic syndromes (MDS), and European LeukemiaNet (ELN) 2010 intermediate-risk (IR) or adverse-risk (AR) acute myeloid leukemia (AML) in the Connect® MDS/AML registry. Tomlinson BK, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji R, Roboz GJ, Savona MR, Sekeres, MA, Flick ED, Kiselev P, Louis CU, Nifenecker M, Swern AS, Erba HP, Steensma DP, Scott BL. *Biol Blood Marrow Transplant*. 2020;26(suppl 3):S98-99.

2019

Diagnostic testing patterns and concordance with World Health Organization (WHO) criteria for patients (Pts) with newly diagnosed (ND) myelodysplastic syndromes (MDS) in the Connect® MDS/AML registry. George TI, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji R, Savona M, Scott BL, Sekeres MA, Steensma DP, Flick ED, Kiselev P, Louis CU, Nifenecker M, Swern AS, Foucar K. *Blood*. 2019;132(suppl 1):4747.

Diagnostic testing patterns for ring sideroblasts (RS) in patients with newly diagnosed lower-risk myelodysplastic syndromes (LR-MDS) in the Connect[®] MDS/AML disease registry. Patel J, Cogle C, Foucar K, Grinblatt D, Komrokji R, Savona M, Scott B, Sekeres M, Steensma D, Flick ED, Kiselev P, Louis C, Nifenecker M, Swern A, George T. *Clin Lymph Myeloma Leuk*. 2019;13(suppl 1):S343-344.

Healthcare resource utilization (HCRU) in patients (Pts) with newly diagnosed (ND) acute myeloid leukemia (AML) treated in the Connect[®] MDS/AML disease registry. Mukherjee S, Abedi M, Erba HP, Pollyea DA, Roboz GJ, Thompson MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Cogle CR. *Hemasphere*. 2019;3(suppl 1):PS1500.

Disease severity is associated with the decision to initiate early treatment in patients with myelodysplastic syndromes (MDS) in the Connect[®] MDS/AML disease registry. Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji R, Savona MR, Scott BL, Sekeres MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Steensma DP. Abstract number MDS19-0060.

2018

Factors associated with early therapy initiation in patients (pts) with myelodysplastic syndromes (MDS) in the Connect[®] MDS/AML disease registry. Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Savona MR, Scott BL, Sekeres MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Steensma DP. *Blood*. 2018;132:4731.

Healthcare resource utilization (HCRU) in patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) treated in the Connect[®] MDS/AML disease registry. Mukherjee S, Abedi M, Erba HP, Pollyea DA, Roboz GJ, Thompson MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Cogle CR. *Blood*. 2018;132:4736.

Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect[®] MDS/AML disease registry. Cogle CR, Pollyea DA, Abedi M, Thompson MA, Roboz GJ, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Erba HP. *J Clin Oncol*. 2018;36(suppl 15):7037.

2017

Antecedent conformity of diagnostic and molecular testing patterns in clinical practice for newly diagnosed acute myeloid leukemia with American Society of Hematology and College of American Pathologists Guidelines. George T, Foucar K, Pollyea D, Erba H, Thompson M, Roboz G, Pagel J, Cogle C, Nifenecker M, Swern A, Kiselev P, Sugrue M. *Am J Clin Pathol*. 2018;149(suppl 1):S82-83.

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the Connect[®] MDS/AML disease registry. Pollyea D, George T, Foucar K, Erba H, Thompson M, Roboz G, Landau D, Pagel J, Seiter K, Cogle C, Nifenecker M, Swern A, Kiselev P, Sugrue M. *Haematologica*. 2017;102(s2):E923.

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the Connect MDS/AML disease registry. Pollyea DA, George T, Foucar KM, Erba HP, Thompson MA, Abedi M, Roboz GJ, Landau D, Pagel JM, Seiter K, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. *J Clin Oncol*. 2017;35(suppl 15):7022.

Current diagnosis patterns for acute myeloid leukemia: concordance between clinical practice (Connect® disease registry) and WHO 2008 recommendations. George TI, Erba HP, Pollyea DA, Abedi M, Roboz GJ, Thompson MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K, on behalf of the Connect MDS/AML Disease Registry Scientific Steering Committee. *Leuk Res.* 2017;55(suppl 1):S106.

2016

Current diagnosis patterns for acute myeloid leukemia (AML) in clinical practice compared with World Health Organization (WHO) 2008 recommendations: outcomes from the Connect® Myelodysplastic Syndromes (MDS) and AML disease registry. George TI, Erba HP, Steensma DP, Pollyea DA, Abedi M, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki D, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Thompson MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K. *Blood.* 2016;128:3548.

2015

Connect MDS and AML: the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. Steensma D, Abedi M, Bejar R, Cogle C, Foucar K, Garcia-Manero G, George T, Grinblatt D, Komrokji R, Maciejewski J, Pollyea D, Roboz G, Savona M, Scott B, Sekeres M, Thompson M, Sugrue M, Swern A, Nifenecker M, H Erba. *Leuk Res.* 2015; 39(suppl 1):S124.

2014

Connect MDS and AML: the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, Pollyea DA, Roboz GJ, Savona M, Scott BL, Sekeres MA, Thompson MA, Zernovak O, Sugrue MM, Swern AS, Nifenecker M, Erba HP. *J Clin Oncol.* 2014;32(suppl 15):TPS7126.